Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of CBx cannabinoid receptor modulators as potassium channel modulators

A technology of modulators and channels, applied in the field of use of CBx cannabinoid receptor modulators as potassium channel modulators, capable of solving problems such as the absence of coronary disease

Inactive Publication Date: 2009-05-13
SOLVAY PHARMA GMBH
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, according to information from the American Heart Federation, the term "Syndrome X" additionally refers to a cardiac condition in which there is chest pain and ECG changes (which suggest ischemic heart disease) but no angiographic findings of coronary disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of CBx cannabinoid receptor modulators as potassium channel modulators
  • Use of CBx cannabinoid receptor modulators as potassium channel modulators
  • Use of CBx cannabinoid receptor modulators as potassium channel modulators

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] In a specific embodiment of the present invention, CB x Regulator used as K ATP Channel modulators for preventing, treating, delaying the progression of, delaying the onset of, and / or inhibiting disease, which is obesity, diabetes, metabolic syndrome, syndrome X, insulinoma, Familial hyperinsulinemic hypoglycemia, male pattern baldness, detrusor hyperactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebrovascular Spasticity, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence. More specifically, if CB x Modulators are used to prevent metabolic syndrome and / or syndrome X, treat metabolic syndrome and / or syndrome X, delay the progression of metabolic syndrome and / or syndrome X, delay the progression of metabolic syndrome and / or syndrome X Onset and / or suppression of Metabolic Syndrome and / or Syndrome X, it being...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and / or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and / or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.

Description

technical field [0001] The present invention relates to CB x Regulator as K ATP New uses of channel modulators. The present invention also relates to methods of treating, preventing, delaying the progression of, delaying the onset of, and / or inhibiting disease, said disease being obesity, diabetes, metabolic syndrome, syndrome X, insulinoma in mammals and humans , familial hyperinsulinemic hypoglycemia, male pattern baldness, detrusor hyperactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina pectoris, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral Vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence, the method comprising administering to a subject in need thereof an effective amount of at least one of the K ATP CB of channel modulator x Conditioner. Background technique [0002] Obesity in the present invention is meant to include any increase i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/353A61K31/425A61K31/415A61K31/454A61K31/09A61K31/542A61K31/5415A61P3/04A61P3/10A61P9/06A61P9/10A61P13/10A61P15/10A61P17/14A61P25/28
CPCA61K31/353A61K31/454A61K31/5415A61K31/542A61K31/425A61K31/09A61K31/415A61P3/00A61P3/04A61P3/06A61P3/10A61P9/00A61P9/06A61P9/10A61P9/12A61P11/06A61P13/00A61P13/10A61P15/00A61P15/10A61P17/00A61P17/14A61P19/06A61P25/00A61P25/04A61P25/08A61P25/28A61P35/00A61P43/00
Inventor J·安特尔P-C·格雷戈里J·H·M·兰格M·菲恩格斯D·赖歇
Owner SOLVAY PHARMA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products